Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
INO This pumping talk of "buyout" is totally ridiculous!
Inovio has nothing to buy out, except a very, very poor reputation.
What is it going to sell? Chairs and desks? Auction companies handle this kind of thing.
Inovio should do one honest thing in its life and close, distributing the remaining money to shareholders.
Here's a link for Inovio: https://www.facebook.com/jaysugarmanauctions
INO Of course someone serving as a board mod can offer their opinion.
Here, you're a mod and you have given your opinion countless times:
INO WARNING: STAY AWAY FROM INOVIO
IT'S A LONG RUNNING PUMP & DUMP, WITH NO APPROVED PRODUCT AFTER 43 YEARS.
It's a penny stock with a value of less than .12 (12 cents) at tonight's close, when the two most recent Reverse Splits are accounted for.
Serial penny stock promoter Avtar Dhillon, an Inovio Founder, Inovio President, Inovio CEO, Inovio Director and Inovio Chairman & Paid Consultant to Inovio to 2019 is currently charged with multiple counts of stock fraud and obstruction of justice related to two of his other penny stock scams, and is awaiting trial in Massachusetts
THE ONES CHATTING THIS STOCK UP ARE TRADERS WHO KNOW FULL WELL THE STOCK IS A POS. THEY HAVE BOT SOME ON THE HOPE THET CAN PUMP IT.
YOU ARE THE MARK. THEY WANT YOU IN. THEY WANT YOUR MONEY.
STAY FAR AWAY FROM THIS DISREPUTABLE STOCK.
MiamiGent
Father of The Inovio Scam Expose.
No position in Inovio whatsoever for at least a half dozen years.
Was not burnt by Inovio.
50,000 online stock posts of integrity, all as MiamiGent
DISCLAIMER The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
Great news, lol
1.915 -0.075 (-3.77%)
INO
Long time Pump & Dump.
Stay away. Bag holder are legion.
MG
No position in about a half dozen years.
Wasn't burnt. Just hate P&Ds, esp. the unconscionable pumpers who surround INO.
LOL
I now wish for WHO to announce positive results of INO-4800, issue an EUA and INO to receive initial hard orders for INO-4800 totaling 500 million doses.
Opus X
ASCO 2022 Abstract REGN and INO.
Very positive. I'm still reading through. Would like to see INO and REGN put a combined press release out on this tomorrow.
https://meetings.asco.org/abstracts-presentations/207038
Conclusions:
INO-5401 + INO-9012 has an acceptable risk/benefit profile and elicits robust immune responses that correlate with enhanced survival when administered with cemiplimab and RT/TMZ to newly diagnosed GBM patients. Pre-treatment gene expression signatures in MGMT-unmethylated patients were statistically associated with OS18. Overall, INO-5401 elicits antigen-specific T cells that can infiltrate GBM tumors. Clinical trial information: NCT03491683.
Opus X
Back to garbage status, where this belongs.
INO What does this have to do with Inovio?
Inovio doesn't have a vaccine. It has never had a vaccine in 43 years.
And it recently threw in the towel on the latest one it was trying for.
MG
Father of The Inovio Scam Expose
ever heard of biologic warfare? you don't tell them everything or what you got in the dod /usa stockpile...........maybe a reason the strategic stockpile gets caught without enough baby elemental/meaning chemicals? formula.......
ppe's
need to have the national security committees of congress have access to the logistics/supply/orders for the national stockkpile..........
have we ever heard about the national diesel reserves till now? is it current and ready? is it where it should be? or did they use it for vaccines? plastics? etc?
INO But not with Inovio.
Big pharma sees Inovio has nothing and anyway they would not want any association with a failed penny company*, a founder of which, as well as President, Director, Chairman and Paid Constant to his own company until 2019, Avtar Dhillon, was arrested in September for multiple counts of stock fraud and obstruction related to two other penny stocks he promoted.
MG
* penny stock when two most recent R/S are accounted for are
More biotech mergers and acquisitions
There is a good case for it, though. “Big pharma has so much cash they could basically buy the whole midcap universe,” notes Yee. Their cumulative cash balance has now risen to more than $300B “The CFOs of big pharma are looking at this carnage, and they are just licking their chops,” says McDonald. “You are probably going to see substantially more transactions down here.”
Inovio Pharmaceuticals Says There Has Been No Further Work Done On Monkeypox Vaccine Since NCBI Publication In 2010; Says Co's DNA Medicines Platform Has The Potential To Allow Us To Respond To Emerging Infectious Diseases
………
https://www.benzinga.com/amp/content/27309891
I don’t see monkey or smallpox in their pipeline, so it was probably just a headline back in the day.
……
https://s23.q4cdn.com/479936946/files/doc_downloads/2022/05/INOVIO-Investor-Presentation-May-2022.pdf
Guess that is why it is up so much today. After all the COVID and cancer talk wouldn't it be funny if monkey pox would be the savior of the company. I say don't look a gift horse in the mouth. And Kim is not around to muddy the waters so hopefully Shea can get something to the market.
They already have one. From 2010 - what happened.
……..
https://www.drugdiscoverytrends.com/inovio-smallpox-vaccine-protects-against-monkeypox/
I hear INO can create a vaccine for monkey pox in 3 hours! (Sarcasm if you don't recognize it)
Way off? Sold in high twenties! If making money is bad advice haha!
INO Why is he getting continual stock options? The company hasn't done chit!
MY advise has borne true- that INO is a POS stock and the chart agrees!
Your advise, on the other hand, has been way off:
To pay the tax’s on his options! Wow no one should take investing advice from you!
INO Inovio Insider David B. Weiner sold shares this week.
INO You edited my sentence, cutting off, "in my opinion".
Of course someone serving as a board mod can offer their opinion.
Here, you're a mod and you have given your opinion right along:
Quote:
Tamtam
Friday, December 25, 2020 10:13:30 AM
Post# 6424135213
Agree newbees should invest in well grounded companies like INO
Quote:
Tamtam
Tuesday, November 10, 2020 5:54:32 PM
Post# 34430
INO 's Vaccine is way better than the competitors!! Whish more people realise that so $30 will be a piece of cake.
INO "Hostile takeover" LOL
INO Buy what? Inovio has nothing.
For forty-three years Inovio has been searching for its raison d'etre. Some moustache to cover it's exorbitant stock awards and salaries and not one single approved product to show for it!
Inovio is a farce!
MG
Father of The Inovio Scam Expose
INO What??
"short term rise in share price"
INO Inovio fell 25.18% last week! It would have fallen even more but for some short covering to harvest huge profits.
MG
Father of The Inovio Scam Expose
Strong Candidate for Acquisition
I think the short term rise in share price will be initially by the prospect that now since Dr. Kim is gone, there will be attempts to acquire INO.
IMO, I would attempt to do that before further information is released on the WHO and China INO-4800 results.
After that it will get much more expensive and may have to be a hostile takeover which could be done if the institutional investors are tired of this which it looks like some are with reduction in holdings to 88 million shares.
Opus X
A fair assessment. Thanks for posting gew59.
-----
The thing folks need to get their head around is Inovio has never had anything. It's a cushy public company that has been searching for forty three years for something to justify its existence.
Inovio was brought along for years by criminally indicted, reviled penny stock promoter Avtar Dhillon. It's not hard to believe the primary goal was continuous stock awards and high salaries, with the not close secondary pursuit being trying to latch onto something plausible, something to keep the story going, the stock awards and salaries.
This company has been a scam since day one.
Inovio Founder, President, CEO, Director and Chairman and Paid Consultant to his own longtime company, Avtar Dhillon, is likely to get his comeuppance for screwing naive investors duped by his slick PRs. The governmentent wins about 95% of the cases it brings to trial.
I wish the government would dig into Inovio. It has been a scam since inception, a stain on the stock market and the financial ruination of many a taken-in investor.
Avtar Dhillon is a real POS (piece of salami) and Inovio is, too!
MiamiGent
Father of The Inovio Scam Expose
INO Well, we know Inovio's Mr. Everything, Dirty Avtar Dhillon was arrested and charged with stock fraud and obstruction related to two other stocks. Deceiver Dhillon did not break off from Inovio until 2019, very likely the heat on him then. The gov't works a year or two before charging. Kim was Defrauder Dhillon's protegee. Dhillon needed a front man because long before he was in trouble with the gov't, he was reviled in the stock market for his scams.
I don't for a minute believe double-crosser Dhillon was squeaky clean during his incredibly long tenure at Inovio, as Inovio President, CEO, Director and Chairman & highly Paid Consultant to Inovio into 2019.
Who knows if the klieg lights will be shone on Inovio
Blowhard Kim was with associated with Double Dealer Dhillon those many years- that's a very poor association! They say, "you are the company you keep"
MG
Father of The Inovio Scam Expose
INO No US agency will be touching Inovio going forward, in my opinion. It's a poor association. Bureaucrats worry about missteps, appearances.
MG
Father of The Inovio Scam Expose
WHO and MPP announce agreement with NIH for COVID-19 health technologies
12 May 2022 News release Geneva Reading time: 2 min (499 words)
WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the United States National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
The licenses, which are transparent, global and non-exclusive, will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries and help put an end to the pandemic.
The 11 COVID-19 technologies offered under two licences include the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics. The full list of the NIH COVID-19 technologies covered in the agreement is here.
“I welcome the generous contribution NIH has made to C-TAP and its example of solidarity and sharing,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Whether it’s today’s pandemic or tomorrow’s health emergency, it’s through sharing and empowering lower-income countries to manufacture their own health tools that we can ensure a healthier future for everyone.”
“We are honoured to sign these public health-driven licence agreements with NIH under the auspices of C-TAP with the goal of providing equitable access to life-saving health products for the most vulnerable in the world,” said Charles Gore, MPP Executive Director.
“NIH were the first to share their patents with MPP for an HIV product back in 2010 when we were created, and we are delighted to continue strengthening our partnership. It is clear that MPP’s model works across different health technologies.”
The announcement was made today by the US Government at the second Global COVID-19 Summit, co-hosted by the United States, Belize, Germany, Indonesia and Senegal.
Licensing the NIH technologies to MPP under the auspices of C-TAP will allow greater access to these technologies and hopefully lead to the development of commercial products that can address current and future public health needs. In most circumstances, NIH will not collect royalties on sales of products licensed in 49 countries classified by the United Nations as Least Developed Countries.
Launched in 2020 by the WHO Director-General and the President of Costa Rica, and supported by 43 Member States, C-TAP aims to facilitate timely, equitable and affordable access to COVID-19 health products by boosting their production and supply through open, transparent and non-exclusive licensing agreements. MPP provides the licensing expertise to this initiative and holds the licences.
The 11 technologies include:
WHO and MPP announce agreement with NIH for COVID-19 health technologies
12 May 2022 News release Geneva Reading time: 2 min (499 words)
WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the United States National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
The licenses, which are transparent, global and non-exclusive, will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries and help put an end to the pandemic.
The 11 COVID-19 technologies offered under two licences include the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics. The full list of the NIH COVID-19 technologies covered in the agreement is here.
“I welcome the generous contribution NIH has made to C-TAP and its example of solidarity and sharing,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Whether it’s today’s pandemic or tomorrow’s health emergency, it’s through sharing and empowering lower-income countries to manufacture their own health tools that we can ensure a healthier future for everyone.”
“We are honoured to sign these public health-driven licence agreements with NIH under the auspices of C-TAP with the goal of providing equitable access to life-saving health products for the most vulnerable in the world,” said Charles Gore, MPP Executive Director.
“NIH were the first to share their patents with MPP for an HIV product back in 2010 when we were created, and we are delighted to continue strengthening our partnership. It is clear that MPP’s model works across different health technologies.”
The announcement was made today by the US Government at the second Global COVID-19 Summit, co-hosted by the United States, Belize, Germany, Indonesia and Senegal.
Licensing the NIH technologies to MPP under the auspices of C-TAP will allow greater access to these technologies and hopefully lead to the development of commercial products that can address current and future public health needs. In most circumstances, NIH will not collect royalties on sales of products licensed in 49 countries classified by the United Nations as Least Developed Countries.
Launched in 2020 by the WHO Director-General and the President of Costa Rica, and supported by 43 Member States, C-TAP aims to facilitate timely, equitable and affordable access to COVID-19 health products by boosting their production and supply through open, transparent and non-exclusive licensing agreements. MPP provides the licensing expertise to this initiative and holds the licences.
The 11 technologies include:
The 11 technologies include:
Prefusion spike proteins (Vaccine Development)
Structure-Based Design of Spike Immunogens (Research Tool for Vaccine Development)
Pseudotyping Plasmid (Research Tool for Vaccine Development)
ACE2 Dimer construct (Research Tool for Drug Development)
Synthetic humanized llama nanobody library and related use (Research Tool for Drug and Diagnostic Development)
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized Spikes (Vaccine Candidate)
Parainfluenza virus 3 based vaccine (Vaccine Candidate)
A VSV-EBOV-Based Vaccine (Vaccine Candidate)
RNASEH-Assisted Detection Assay for RNA (Diagnostic)
Detection of SARS-CoV-2 and other RNA Virus (Diagnostic)
High-Throughput Diagnostic Test (Diagnostic)
Get out now??
INO’s Intro disclaimer>>>
DISCLAIMER The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
No it didn’t hit ten cents today. We’re living in the present not the far away past.
INO Get out now, in my opinion.
It'll go under a dollar and then they will do a R/S to get in compliance.
I haven't had any position in INO in about seven years or more.
I recollect having no losses on INO. Certainly nothing of consequence.
I just couldn't stand to see this scam going on.
The pumpers who surrounded this stock are evil, as bad as the Inovio. The company could never have continued without their abetting.
MG
INO Here's a typical warning from me, dated December, 2021
MiamiGent
Friday, December 17, 2021 10:36:48 PM
Post# 39683 of 40210
INO The stun guy is discarded technology. Inovio picked it up at the equivalent of a bio yard sale price. Inovio has milked it for pumping PR's these many years.
Folks, stay away from Inovio. It's a failed company, masterminded by penny stock promoter, Avtar Dhillon, currently awaiting trial for stock fraud and obstruction of Justice.
MG
Father of The Inovio Scam Expose
INO I have been consistently railing against INO since July of 2013 !!
A scam !!!
https://investorshub.advfn.com/boards/boardposters.aspx?boardid=13093
INO Inovio hit .10 today (ten cents), when two most recent R/S are accounted for.
What does ten cents buy today? One of three things- a pencil, a lollipop or a share of Inovio (INO)
Nothing at the Dollar Store.
Stay away from this Pump & Dump. Bag holders are legion. Conceivably as many INO investors have died waiting 43 years for Inovio to produce one, single approved drug, vaccine or therapy as there are now dead Russian invaders. Both ugly stains on humankind!
MG
Father of The Inovio Scam Expose
Inovio's longtime CEO is out as Covid vaccine laggard throws in the towel on PhIII, pivots to booster
Stepping down to make room for Jacqueline Shea — who first joined Inovio as COO in 2019 — Kim leaves behind a legacy of boisterous claims and promises about DNA vaccines over decades and a habit of capitalizing on pandemics but no approved product to show for it.
Shea will be overseeing a change in direction as Inovio, a laggard in the Covid-19 vaccine race, shutters a Phase III trial in favor of a booster strategy.
Not sure why favoring "Booster" if they are giving up on Covid vaccine all together, what is the point ??
https://endpts.com/inovios-longtime-ceo-is-out-as-covid-vaccine-laggard-throws-in-the-towel-on-phiii-pivots-to-booster/
9:20a ET 5/11/2022 - MarketWatch
Inovio Pharmaceuticals stock price target cut to $1 from $3 at Stifel Nicolaus
Mentioned: INO
(END) Dow Jones Newswires
May 11, 2022 09:20 ET (13:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Well, that was an interesting conference call.
Thank MG for the reminder. Quarterly excuse call.
……
https://ir.inovio.com/investors-and-media/default.aspx
INO Inovio hit .1650 today (sixteen and a half cents), when two most recent R/S are accounted for.
Stay away from this Pump & Dump!
Hundreds and hundreds of INO investors have died waiting 43 years for Inovio to produce a single approved drug.
MG
Father of The Inovio Scam Expose
Information for new readers/investors which should do their own DD and find out this company
- has an impressive list of partners https://www.inovio.com/about-inovio/partnerships/overview/
- has an impressive leadership team https://www.inovio.com/about-inovio/leadership/
- has an impressive board of directors https://www.inovio.com/about-inovio/board-of-directors/
Be aware of the false rumors
- Avtar Dhillon never was INO's founder https://www.wsj.com/market-data/quotes/INO/company-people/executive-profile/77702278
- Avtar Dhillon is not a company consultant nor has he any ties with the company since several years.
- INO is trading on the Nasdaq and is not a penny stock since more than 7 years
- INO 4800 has not FDA failed phase two as they rteceived clearance for phase three https://ir.inovio.com/news-releases/default.aspx
TT the exposer of false statements.
False information Avtar Dhillon never was INO’s founder
Inovio!-Wow!- https://www.linkedin.com/posts/jpeocbrnd_jpeocbrnd-cbrn-biotechnology-activity-6925813173111410690-Nf-G
Meet the CELLECTRA 3PSP. This handheld, battery-operated device opens cells with electrical pulses to better deliver DNA vaccines. It can deliver 100 doses with a single battery charge and is designed for easy transport. Our JPL CBRND Enabling Biotechnologies team works with INOVIO Pharmaceuticals, Inc., the creator of the CELLECTRA 3PSP, to support the large-scale manufacturing of this tool.
CBRN warfighters often serve in environments without electricity or medical centers. The CELLECTRA 3PSP is designed to function reliably in these environments and can be stockpiled without maintenance, ensuring that our warfighters can get the vaccines they need anywhere.
#JPEOCBRND #CBRN #Biotechnology #vaccines
Denmark becomes the first country to halt its Covid vaccination program
………
https://www.cnbc.com/amp/2022/04/28/denmark-the-first-country-to-halt-its-covid-vaccination-program.html
Followers
|
632
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
40491
|
Created
|
07/25/08
|
Type
|
Free
|
Moderators |
DISCLAIMER The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Whatch out for fake comments by manipulators
https://www.griproom.com/fun/how-to-spot-fake-comments-on-stock-boards
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |